Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C19 Antibodies (33) and CYP2C19 Kits (20) and many more products for this protein.
Showing 3 out of 3 products:
CYP2C19 polymorphism does not affect rosuvastatin pharmacokinetics in healthy Taiwanese in a clinically meaningful way.
On-treatment platelet reactivity was compared between patients stratified by diabetes mellitus (DM), CYP2C19*2 status and clopidogrel dose. Both DM and CYP2C19*2 were independently associated with elevated on-treatment platelet reactivity with clopidogrel 75 mg daily.
REVIEW: CYP2C19 and CYP2D6 (show CYP2D6 Proteins) genotypes in Pacific peoples
PON1 (show PON1 Proteins) and CYP2C19 polymorphisms were associated with lower clopidogrel responsiveness in this sample. Despite differences in CYP2C19 polymorphisms across white and non-white patients, genetic admixture by itself was not able to identify clopidogrel hyporesponsiveness.
The study showed that the CYP1A2 (show CYP1A2 Proteins) (-163C>A) Rs762551 C/C genotype was associated with an increased risk of age-related macular degeneration.
Genetic testing of CYP2C19 may help in prescribing a dose according to genetic makeup and represent the initial steps towards the development of diagnostic tests and therapeutic strategies that will substantially improve human health.
rs4244285 of CYP2C19 have the main effects on coronary heart disease risk.
The poor metabolizer (PM) group had the lowest metabolic ratio and exhibited the highest area under the curve (AUC) for omeprazole among the CYP2C19 phenotype groups.
The carriage of the cytochrome P450 CYP2C19 681A allele rather than platelet receptor gene polymorphisms increased extent of platelet aggregation induced by dual antiplatelet therapy in patients with Coronary heart disease .
coadministration, voriconazole AUC and Cmin decreased by 33% and 39% respectively, in CYP2C19 extensive-metabolizers, whereas voriconazole Cmax and AUC increased 4.4-fold and 5.6-fold respectively, in poor-metabolizers
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P450 2C
, (R)-limonene 6-monooxygenase
, (S)-limonene 6-monooxygenase
, (S)-limonene 7-monooxygenase
, S-mephenytoin 4-hydroxylase
, cytochrome P-450 II C
, cytochrome P450 2C19
, cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19
, cytochrome P450-11A
, cytochrome P450-254C
, flavoprotein-linked monooxygenase
, mephenytoin 4'-hydroxylase
, mephenytoin 4-hydroxylase
, microsomal monooxygenase
, xenobiotic monooxygenase